[go: up one dir, main page]

AR088838A1 - Derivados de imidazol como inhibidores del virus de la hepatitis c - Google Patents

Derivados de imidazol como inhibidores del virus de la hepatitis c

Info

Publication number
AR088838A1
AR088838A1 ARP120104251A ARP120104251A AR088838A1 AR 088838 A1 AR088838 A1 AR 088838A1 AR P120104251 A ARP120104251 A AR P120104251A AR P120104251 A ARP120104251 A AR P120104251A AR 088838 A1 AR088838 A1 AR 088838A1
Authority
AR
Argentina
Prior art keywords
diyl
imidazol
pyran
bis
biphenyldiylbis
Prior art date
Application number
ARP120104251A
Other languages
English (en)
Inventor
Belema Makonen
Yang Zhong
A Bender John
R St Laurent Denis
N Nguyen Van
Wang Gan
Lee Romine Jeffrey
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR088838A1 publication Critical patent/AR088838A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos, composiciones y métodos para el tratamiento de la infección por el virus de la hepatitis C (HCV). También composiciones farmacéuticas que contienen dichos compuestos y métodos para usar estos compuestos en el tratamiento de la infección por HCV. Reivindicación 1: Un compuesto caracterizado porque se selecciona de: ((R,S,R,1S,1S)-((2S,2S,5S,5S)-5,5-(5,5-([1,1-bifenil]-4,4-diil)bis(1H-imidazol-5,2-diil))bis(2-metilpirrolidin-5,1-diil))bis(1-((2R,4R,6S)-2-ciclopropil-6-metiltetrahidro-2H-piran-4-il)-2-oxoetan-2,1-diil))dicarbamato de dimetilo; ((S,R,R,1S,1S)-((2S,2S,5S,5S)-5,5-(5,5-([1,1-bifenil]-4,4-diil)bis(1H-imidazol-5,2-diil))bis(2-metilpirrolidin-5,1-diil))bis(1-((2S,4R,6R)-2-ciclopropil-6-metiltetrahidro-2H-piran-4-il)-2-oxoetan-2,1-diil))dicarbamato de dimetilo; ((S,R,S,1S,1S)-((2S,2S,5S,5S)-5,5-(5,5-([1,1-bifenil]-4,4-diil)bis(1H-imidazol-5,2-diil))bis(2-metilpirrolidin-5,1-diil))bis(1-((2R,4S,6S)-2-ciclopropil-6-metiltetrahidro-2H-piran-4-il)-2-oxoetan-2,1-diil))dicarbamato de dimetilo; (4,4-bifenildiilbis(1H-imidazol-4,2-diil((2S,5S)-5-metil-2,1-pirrolidindiil)(1-(3-ciano-3-metilciclobutiliden)-2-oxo-2,1-etandiil)))biscarbamato de dimetilo; y (4,4-bifenildiilbis(1H-imidazol-4,2-diil((2S,5S)-5-metil-2,1-pirrolidindiil)(1-(3-ciano-3-metilciclobutiliden)-2-oxo-2,1-etandiil)))biscarbamato de dimetilo; o una sal de este aceptable desde el punto de vista farmacéutico. Reivindicación 2: Un compuesto caracterizado porque se selecciona de: (4,4-bifenildiilbis(1H-imidazol-5,2-diil((2S,5R)-5-etinil-2,1-pirrolidindiil)((1S)-1-((2R,6R)-2,6-dimetiltetrahidro-2H-piran-4-il)-2-oxo-2,1-etandiil)))biscarbamato de dimetilo; (4,4-bifenildiilbis(1H-imidazol-4,2-diil((2S,5S)-5-etinil-2,1-pirrolidindiil)((1S)-1-((2R,6R)-2,6-dimetiltetrahidro-2H-piran-4-il)-2-oxo-2,1-etandiil)))biscarbamato de dimetilo; (4,4-bifenildiilbis(1H-imidazol-4,2-diil((2S,5R)-5-(hidroximetil)-2,1-pirrolidindiil)((1S)-1-((2R,6R)-2,6-dimetiltetrahidro-2H-piran-4-il)-2-oxo-2,1-etandiil)))biscarbamato de dimetilo; (4,4-bifenildiilbis(1H-imidazol-4,2-diil((2S,5R)-5-(hidroximetil)-2,1-pirrolidindiil)((1S)-1-((2R,6R)-2,6-dimetiltetrahidro-2H-piran-4-il)-2-oxo-2,1-etandiil)))biscarbamato de dimetilo; (4,4-bifenildiilbis(1H-imidazol-4,2-diil(3S)-2-azaspiro[4.4]nonan-3,2-diil((1S)-1-((2R,6R)-2,6-dimetiltetrahidro-2H-piran-4-il)-2-oxo-2,1-etandiil)))biscarbamato de dimetilo; y (4,4-bifenildiilbis(1H-imidazol-4,2-diil((2S,4R)-4-(ciclopropilmetil)-2,1-pirrolidindiil)((1S)-1-((2R,6R)-2,6-dimetiltetrahidro-2H-piran-4-il)-2-oxo-2,1-etandiil)))biscarbamato de dimetilo; o una sal de te aceptable desde el punto de vista farmacéutico. Reivindicación 3: Un compuesto caracterizado porque se selecciona de: (4,4-bifenildiilbis(1H-imidazol-5,2-diil((2S,5S)-5-metil-2,1-pirrolidindiil)((1S)-1-(2-oxaspiro[3.3]hept-6-il)-2-oxo-2,1-etandiil)))biscarbamato de dimetilo; (4,4-bifenildiilbis(1H-imidazol-4,2-diil((2S,5S)-5-metil-2,1-pirrolidindiil)((1S)-1-((2R,4R,4aS,7aS)-2-metiloctahidrociclopenta[b]piran-4-il)-2-oxo-2,1-etandiil)))biscarbamato de dimetilo; y (4,4-bifenildiilbis(1H-imidazol-4,2-diil((2S,5S)-5-metil-2,1-pirrolidindiil)((1S)-1-((2R,4S,4aS,7aS)-2-metiloctahidrociclopenta[b]piran-4-il)-2-oxo-2,1-etandiil)))biscarbamato de dimetilo; o una sal de este aceptable desde el punto de vista farmacéutico. Reivindicación 4: Un compuesto caracterizado porque es el: ((R,S,S,1S,1S)-((2S,2S,5S,5S)-5,5-(5,5-([1,1-bifenil]-4,4-diil)bis(1H-imidazol-5,2-diil))bis(2-metilpirrolidin-5,1-diil))bis(1-((2S,4S,6R)-2-ciclopropil-6-metiltetrahidro-2H-piran-4-il)-2-oxoetan-2,1-diil))dicarbamato de dimetilo; o una sal de este aceptable desde el punto de vista farmacéutico.
ARP120104251A 2012-10-24 2012-11-09 Derivados de imidazol como inhibidores del virus de la hepatitis c AR088838A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/061623 WO2014065791A1 (en) 2012-10-24 2012-10-24 Hepatitis c virus inhibitors

Publications (1)

Publication Number Publication Date
AR088838A1 true AR088838A1 (es) 2014-07-10

Family

ID=47116511

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120104251A AR088838A1 (es) 2012-10-24 2012-11-09 Derivados de imidazol como inhibidores del virus de la hepatitis c

Country Status (7)

Country Link
US (2) US20150252028A1 (es)
EP (1) EP2912031B1 (es)
JP (1) JP6196678B2 (es)
CN (1) CN104884455B (es)
AR (1) AR088838A1 (es)
TW (1) TW201416363A (es)
WO (1) WO2014065791A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
CN105530933B (zh) 2013-07-17 2018-12-11 百时美施贵宝公司 用于治疗hcv的包含联苯衍生物的组合产品
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2018213140A1 (en) * 2017-05-15 2018-11-22 Zeno Royalties & Milestones, LLC Analgesic compounds
UY39484A (es) 2020-11-02 2022-06-30 Novartis Ag Inhibidores de interleucina-17

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003261434A1 (en) 2002-08-12 2004-02-25 Bristol-Myers Squibb Company Iminothiazolidinones as inhibitors of hcv replication
WO2006093867A1 (en) 2005-02-28 2006-09-08 The Rockefeller University Structure of the hepatitits c virus ns5a protein
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20110237636A1 (en) * 2009-03-30 2011-09-29 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8377980B2 (en) * 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2011130146A1 (en) 2010-04-14 2011-10-20 Array Biopharma Inc. 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases
US8552047B2 (en) * 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) * 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Also Published As

Publication number Publication date
WO2014065791A1 (en) 2014-05-01
JP2015535244A (ja) 2015-12-10
CN104884455A (zh) 2015-09-02
US9561212B2 (en) 2017-02-07
CN104884455B (zh) 2017-09-12
EP2912031B1 (en) 2017-05-31
US20160338999A1 (en) 2016-11-24
EP2912031A1 (en) 2015-09-02
US20150252028A1 (en) 2015-09-10
TW201416363A (zh) 2014-05-01
JP6196678B2 (ja) 2017-09-13

Similar Documents

Publication Publication Date Title
PE20110367A1 (es) DERIVADOS DE 4-CIANO-4-FENIL-PIRROLIDIN-2-CARBOXAMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA INTERACCION p53-MDM2
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
PE20140038A1 (es) Compuestos antivirales
ECSP088528A (es) Formulación de profármacos para el vhc
PE20170247A1 (es) Derivados de pirrolidina-2,5-diona, composiciones farmaceuticas y metodos para usar como inhibidores ido1
PE20170898A1 (es) Inhibidor de cinasa aurora a
AR088838A1 (es) Derivados de imidazol como inhibidores del virus de la hepatitis c
CL2012001449A1 (es) Uso de combinaciones del compuesto n-[(ciclopentiloxi)carbonil]-3-metil-l-valiol-(4r)-4-({8-bromo-2-[2-(isobutirilamino)-1,3-tiazol-4-il]-7-metoxi-4-quinolinil}oxi)-n-[(1r,2s)-1-carboxi-2-vinilciclopropil]-l-prolinamida; y envase que comprende las formas de dosificacion.
PE20220569A1 (es) Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y metodos de tratamiento con dichos compuestos
PE20170945A1 (es) Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
PE20142185A1 (es) Pirrolidina-2-carboxamidas sustituidas
EA201100928A1 (ru) Новые 4-амино-4-оксобутаноил-пептиды как ингибиторы репликации вирусов
PE20120993A1 (es) Derivados bifenilicos como antivirales
PE20080951A1 (es) DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
PE20141824A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
PE20121479A1 (es) Inhibidores del virus de la hepatitis c
PE20141075A1 (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina
AR078635A1 (es) Compuestos de pirrolo[2, 3-d]pirimidina, composiciones farmaceuticas que los comprenden y su uso en la elaboracion de un medicamento para el tratamiento de enfermedades mediadas por la quinasa de janus
CO6231036A2 (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
UY30310A1 (es) Derivados 2-azetidinona, sales, solvatos, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
PE20200740A1 (es) Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton
PE20180412A1 (es) Compuestos inhibidores de la senalizacion de la via de notch
EA201070483A1 (ru) Новые офтальмологические композиции
PE20180355A1 (es) Desacetoxitubulisina h y analogos de esta
PE20081850A1 (es) Derivados ciclizados como inhibidores de la eg-5

Legal Events

Date Code Title Description
FB Suspension of granting procedure